Marker Therapeutics, Inc. announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO). This partnership focuses on current good manufacturing practice (cGMP) manufacturing of MT-601, Marker’s lead Multi-Antigen Recognizing (MAR)-T cell therapy.
Under the agreement, Cellipont Bioservices will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker’s APOLLO study. This collaboration is designed to accelerate clinical supply and establish the foundation for a potential pivotal trial and future commercial readiness.
The decision to partner with Cellipont Bioservices follows encouraging clinical data from the APOLLO study, which previously reported a favorable safety profile and objective responses in 7 out of 9 study participants. This manufacturing alliance is a critical step as Marker prepares to advance MT-601 for patients with diffuse large B-cell lymphoma who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.